‘We are bringing a bad name to Islam': Malala condemns Mashal's lynching

April 15, 2017

Apr 15: Pakistani Nobel laureate Malala Yousafzai has strongly criticised the cold-blooded murder of Abdul Wali Khan University student Mashal Khan, who was lynched by a mob over allegations of blasphemy on Thursday.

Malala“This is an incident filled with terror and fear,” Yousafzai said in a video message.

Malala lamented that some Pakistanis have forgotten the message of peace given by Islam, saying: “This was not just the funeral of Mashal Khan, it was the funeral of the message of our religion Islam.”

She said the Holy Prophet (PBUH) had never advised his followers to “be impatient and go around killing people”.

Malala said Pakistani people often complain about the presence of Islamophobia in the West and that other countries are “maligning our name”.

“No one is maligning the name of your country or religion… we ourselves are bringing a bad name to our country and religion,” she said.

Malala, who was anointed a UN Messenger of Peace last week, said it is the right of every Pakistani to live a safe and peaceful life.

She urged the state institutions and political parties to take a stand in order to bring justice to Mashal's family.

The education activist also said she talked over telephone with Mashal's grieving father, who gave a message of “peace and patience”.

23-year-old AWKUM student Mashal was killed and another student, Abdullah, seriously injured on Thursday by a vigilante mob at the campus for allegedly “publishing blasphemous content online”, local police said at the time.

No case had been filed against the two students prior to the incident and police had not been investigating the two on blasphemy charges.

Malala's message (in Urdu) about the tragic assassination of Mashal Khan demanding the government for justice to the family.

Posted by Yousafzai Ziauddin on Friday, April 14, 2017

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
May 25,2020

Islamabad, May 25: Pakistan’s coronavirus cases on Monday reached 56,349 with 1,748 new patients while the death toll climbed to 1,167, the health ministry said.

The Ministry of National Health Services reported that 22,491 cases were diagnosed in Sindh, 20,077 in Punjab, 7,905 in Khyber-Pakhtunkhwa, 3,407 in Balochistan, 1,641 in Islamabad, 619 in Gilgit-Baltistan and 209 in Pakistan-occupied Kashmir.

So far 1,167 people have died of the COVID-19 including 34 who lost their lives in the last 24 hours. A total of 17,482 patients have recovered from the deadly contagion.

The authorities have conducted 483,656 tests in the country, including 10,049 on Sunday. The trajectory showed that the number was steadily going up with authorities fearing a rise in cases in the wake of the easing of lockdown before Eid which was observed in the country on Sunday.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
May 28,2020

Washington, May 28: US President Donald Trump has warned social media giants that his government could "strongly regulate" or "close them down" after Twitter fact-checked one of his tweets for the first time.

"Republicans feel that Social Media Platforms totally silence conservatives voices," Xinhua news agency reported citing Trump as saying in a tweet to his 80 million followers on Wednesday.

"We will strongly regulate, or close them down, before we can ever allow this to happen."

Later in the day, he said that Twitter "has now shown everything we have been saying about them... is correct" and vowed "big action to follow".

The President's remarks came after Twitter slapped a warning label on one of his tweets on Tuesday, cautioning readers "Trump makes unsubstantiated claim that mail-in ballots will lead to voter fraud".

It was in response to Trump's tweet, without providing evidence, said: "There is NO WAY (ZERO!) that Mail-In Ballots will be anything less than substantially fraudulent."

Also Read: Obama was ‘grossly incompetent president’, says Donald Trump
It is unclear what regulatory steps the president could take without new laws passed by Congress, the BBC reported.

The White House is yet to offer further details.

Earlier, Trump has accused Twitter of interfering in this year's US presidential election scheduled for November, saying the company was "completely stifling free speech, and I, as president, will not allow it to happen".

With more than 52,000 tweets currently to his name, Trump is a prolific tweeter and relies on the platform to disseminate his views to millions of people.

He has used Twitter to launch attacks on opponents, with targets ranging from North Korean leader Kim Jong-un to his political rivals in the US.

In 2017 he used anti-Muslim tweets aimed at London Mayor Sadiq Khan to serve a domestic political purpose of warning about immigration.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
March 25,2020

Beijing:  Around 5,000 people have signed up for the phase I clinical trial of recombinant novel coronavirus vaccine in Chinese city Wuhan where the virus first emerged late last year.

The recruitment for participants ended this week with nearly 5,000 volunteers signing up for the trial, state-run Beijing News reported on Wednesday.

A single-centre, open and dose-escalation phase I clinical trial for recombinant novel coronavirus vaccine (adenoviral vector) will be tested in healthy adults aged between 18 and 60 years, according to the ChiCTR (China Clinical Trial Register).

The trial, led by experts from the Academy of Military Medical Sciences, gained its approval on March 16 and the research is expected to last half a year.

Requiring at least 108 participants, the trial will be conducted in Wuhan, capital of Hubei province, the region worst-affected by the virus in the country, state-run China Daily reported.

Participants will experience 14-day quarantine restrictions after being vaccinated and their health condition will be recorded every day.

Chinese scientists are hastening the development of COVID-19 vaccines through five approaches --- inactivated vaccines, genetic engineering subunit vaccines, adenovirus vector vaccines, nucleic acid vaccines and vaccines using attenuated influenza virus as vectors.

So far, most teams are expected to complete preclinical research in April and some are moving forward faster, Wang Junzhi, an academician with the Chinese Academy of Engineering said.

Wang noted that research and development of COVID-19 vaccines in China is not slower than foreign counterparts and has been carried out in a scientific, standardised and orderly way.

China has stepped up the process to finalise vaccines to counter COVID-19 after Kaiser Permanente research facility in Seattle and Washington stole the march and began human trials.

China lifted tough restrictions on the Hubei province on Wednesday after a months-long lockdown as the country reported no new domestic cases.

But there were another 47 imported infections from overseas, the National Health Commission said. In total, 474 imported infections have been diagnosed in China -- mostly Chinese nationals returning home.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.